Janus Henderson Group PLC Ascendis Pharma A/S Call Options Transaction History
Janus Henderson Group PLC
- $194 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
276Shares Held
60MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.12 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$1.02 Billion15.67% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$869 Million1.14% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.58MShares$731 Million0.39% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...